Intestinal Microbiota and Biliary System Diseases

Overview

Journal Front Cell Infect Microbiol

Specialties Cell Biology
Infectious Diseases
Microbiology

Date 2024 Apr 1

PMID 38558851

Authors

Hua Wang

Junfeng Gong

Jingyi Chen

Wei Zhang

Yanjun Sun

Dengqun Sun

Affiliations

Soon will be listed here.

Abstract

Introduction: The incidence of biliary system diseases has been continuously increasing in the past decade. Biliary system diseases bring a heavy burden to humanity and society. However, the specific etiology and pathogenesis are still unknown. The biliary system, as a bridge between the liver and intestine, plays an indispensable role in maintaining the physiological metabolism of the body. Therefore, prevention and treatment of biliary diseases are crucial. It is worth noting that the microorganisms participate in the lipid metabolism of the bile duct, especially the largest proportion of intestinal bacteria.

Methods: We systematically reviewed the intestinal microbiota in patients with gallstones (GS), non-calculous biliary inflammatory, and biliary tract cancer (BTC). And searched Pubmed, Embase and Web of science for research studies published up to November 2023.

Results: We found that the abundance of Faecalibacterium genus is decreased in GS, primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC) and BTC. Veillonella, Lactobacillus, Streptococcus and Enterococcus genus were significantly increased in PSC, PBC and BTC. Interestingly, we found that the relative abundance of Clostridium was generally reduced in GS, PBC and BTC. However, Clostridium was generally increased in PSC.

Discussion: The existing research mostly focuses on exploring the mechanisms of bacteria targeting a single disease. Lacking comparison of multiple diseases and changes in bacteria during the disease process. We hope to provide biomarkers forearly diagnosis of biliary system diseases and provide new directions for the mechanism of intestinal microbiota in biliary diseases.

Citing Articles

Gut microbiome and metabolome characteristics of patients with cholesterol gallstones suggest the preventive potential of prebiotics.

Liu Y, Li H, Sun T, Sun G, Jiang B, Liu M Imeta. 2025; 4(1):e70000.

PMID: 40027485 PMC: 11865347. DOI: 10.1002/imt2.70000.

A Report of a Rare Case of Vagococcus fluvialis Isolated From Urine: Clinical Significance of Vagococcus Species With an Update of the Available Literature.

Shahapur P, Shahapur R, Veggalam S, Kandi V Cureus. 2024; 16(10):e71620.

PMID: 39553042 PMC: 11566384. DOI: 10.7759/cureus.71620.

Glucosinolates and Indole-3-carbinol from L. as inhibitors of CdtB: insights from molecular docking, dynamics, DFT and in vitro assay.

Tasnim F, Hosen M, Haque M, Islam A, Nuryay M, Mawya J In Silico Pharmacol. 2024; 12(2):95.

PMID: 39479380 PMC: 11519271. DOI: 10.1007/s40203-024-00276-3.

Temporal Shifts in Etiological Agents and Antibiotic Resistance Patterns of Biliary Tract Infections in Sichuan Province, China (2017-2023).

Li Y, Li D, Huang X, Long S, Yu H, Zhang J Infect Drug Resist. 2024; 17:4377-4389.

PMID: 39411501 PMC: 11476339. DOI: 10.2147/IDR.S474191.

Exploring the correlation among genetic variants, cholecystectomy and gut microbiome: A Mendelian randomization study.

Yin Y, Zhang X Medicine (Baltimore). 2024; 103(39):e39852.

PMID: 39331944 PMC: 11441970. DOI: 10.1097/MD.0000000000039852.

References

Treem W, Malet P, Gourley G, Hyams J . Bile and stone analysis in two infants with brown pigment gallstones and infected bile. Gastroenterology. 1989; 96(2 Pt 1):519-23. DOI: 10.1016/s0016-5085(89)91579-5. View

Lammert F, Gurusamy K, Ko C, Miquel J, Mendez-Sanchez N, Portincasa P . Gallstones. Nat Rev Dis Primers. 2016; 2:16024. DOI: 10.1038/nrdp.2016.24. View

Heeney D, Gareau M, Marco M . Intestinal Lactobacillus in health and disease, a driver or just along for the ride?. Curr Opin Biotechnol. 2017; 49:140-147. PMC: 5808898. DOI: 10.1016/j.copbio.2017.08.004. View

Ding L, Wang S, Jiang W, Miao Y, Liu W, Yang F . Identification of Intestinal Microbial Community in Gallstone Patients with Metagenomic Next-Generation Sequencing. Diagnostics (Basel). 2023; 13(16). PMC: 10453932. DOI: 10.3390/diagnostics13162712. View

Liu J, Yan Q, Luo F, Shang D, Wu D, Zhang H . Acute cholecystitis associated with infection of Enterobacteriaceae from gut microbiota. Clin Microbiol Infect. 2015; 21(9):851.e1-9. DOI: 10.1016/j.cmi.2015.05.017. View

Ahmed M . Functional, Diagnostic and Therapeutic Aspects of Bile. Clin Exp Gastroenterol. 2022; 15:105-120. PMC: 9309561. DOI: 10.2147/CEG.S360563. View

Song X, Wang X, Hu Y, Li H, Ren T, Li Y . A metagenomic study of biliary microbiome change along the cholecystitis-carcinoma sequence. Clin Transl Med. 2020; 10(2):e97. PMC: 7403721. DOI: 10.1002/ctm2.97. View

Shalon D, Culver R, Grembi J, Folz J, Treit P, Shi H . Profiling the human intestinal environment under physiological conditions. Nature. 2023; 617(7961):581-591. PMC: 10191855. DOI: 10.1038/s41586-023-05989-7. View

Ruhlemann M, Liwinski T, Heinsen F, Bang C, Zenouzi R, Kummen M . Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis. Aliment Pharmacol Ther. 2019; 50(5):580-589. PMC: 6899739. DOI: 10.1111/apt.15375. View

10.

OFlaherty S, Briner Crawley A, Theriot C, Barrangou R . The Bile Salt Hydrolase Repertoire Reveals Niche-Specific Adaptation. mSphere. 2018; 3(3). PMC: 5976879. DOI: 10.1128/mSphere.00140-18. View

11.

Kummen M, Thingholm L, Ruhlemann M, Holm K, Hansen S, Moitinho-Silva L . Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis. Gastroenterology. 2021; 160(5):1784-1798.e0. PMC: 7611822. DOI: 10.1053/j.gastro.2020.12.058. View

12.

Kitahata S, Yamamoto Y, Yoshida O, Tokumoto Y, Kawamura T, Furukawa S . Ileal mucosa-associated microbiota overgrowth associated with pathogenesis of primary biliary cholangitis. Sci Rep. 2021; 11(1):19705. PMC: 8492680. DOI: 10.1038/s41598-021-99314-9. View

13.

Katsika D, Grjibovski A, Einarsson C, Lammert F, Lichtenstein P, Marschall H . Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology. 2005; 41(5):1138-43. DOI: 10.1002/hep.20654. View

14.

van Erpecum K . Pathogenesis of cholesterol and pigment gallstones: an update. Clin Res Hepatol Gastroenterol. 2011; 35(4):281-7. DOI: 10.1016/j.clinre.2011.01.009. View

15.

Tang W, Li D, Hazen S . Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol. 2018; 16(3):137-154. PMC: 6377322. DOI: 10.1038/s41569-018-0108-7. View

16.

Russell D . The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003; 72:137-74. DOI: 10.1146/annurev.biochem.72.121801.161712. View

17.

Rossen N, Fuentes S, Boonstra K, DHaens G, Heilig H, Zoetendal E . The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. J Crohns Colitis. 2014; 9(4):342-8. DOI: 10.1093/ecco-jcc/jju023. View

18.

Wang Q, Jiao L, He C, Sun H, Cai Q, Han T . Alteration of gut microbiota in association with cholesterol gallstone formation in mice. BMC Gastroenterol. 2017; 17(1):74. PMC: 5466737. DOI: 10.1186/s12876-017-0629-2. View

19.

Sayin S, Wahlstrom A, Felin J, Jantti S, Marschall H, Bamberg K . Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013; 17(2):225-35. DOI: 10.1016/j.cmet.2013.01.003. View

20.

Hofmann A . Bile acid secretion, bile flow and biliary lipid secretion in humans. Hepatology. 1990; 12(3 Pt 2):17S-22S; discussion 22S-25S. View